Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
PG-011Gel
Prime Medicine
Atopic Dermatitis
1 trial -
PH94B
Vistagen Therapeutics
Social Anxiety Disorder
1 trial -
PH94B Nasal Spray
Vistagen Therapeutics
Social Anxiety Disorder
2 trials -
PIMECROLIMUS , Amlitelimab, Matched placebo for test, Amlitelimab, -, TACROLIMUS
Sanofi-aventis Healthcare Pty Ltd
Dermatitis atopic
1 trial -
PIMECROLIMUS , Amlitelimab, Placebo, Amlitelimab, -, TACROLIMUS
Sanofi-aventis Healthcare Pty Ltd
Dermatitis atopic
1 trial -
PIPERACILLINE TAZOBACTAM VIATRIS 4 g/0,5 g, poudre pour solution pour perfusion, CEFAZOLIN, Placebo de Cefazoline / Piperaciline / Tazobactam
Pari Pharma GmbH
Excision-autograft surgery in burn patient
1 trial -
PIRTOBRUTINIB, IDELALISIB, RITUXIMAB, BENDAMUSTINE HYDROCHLORIDE, PIRTOBRUTINIB, IDELALISIB
Wuhan Createrna Science and Technology Co., Ltd
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
1 trial -
PLACEBO DE COLCHICINE 1 mg, COLCHICINE OPOCALCIUM 1 mg, comprimΓ© sΓ©cable
Pari Pharma GmbH
patients suffering from acute myocarditis confirmed on Cardiac magnetic resonance imaging.
1 trial -
PLACEBO for GIVINOSTAT hydrochloride monohydrate (ITF2357) 10 mg/mL oral suspension, ITF2357
Italfarmaco S.p.A.
Duchenne muscular dystrophy (DMD)
1 trial -
PLACEBO, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, INFLIXIMAB, DOMVANALIMAB
AstraZeneca AB
The target population of interest in this study is participants with locally advanced (Stage III), unresectable NSCLC, whose tumours express PD L1 TC β₯ 1% as assessed by a central reference laboratory using the VENTANA PD-L1 (SP263) IHC assay, and who did not progress after definitive platinum based cCRT.
1 trial -
PLERIXAFOR, Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM
Vertex Pharmaceuticals (Australia) Pty.
Transfusion-dependent Ξ²-thalassemia (TDT), Severe sickle cell disease (SCD)
1 trial -
PONATINIB, PONATINIB, Ponatinib, IMATINIB, IMATINIB
Takeda
Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
1 trial -
PRAX-114
Chongqing Precision Biotech Co., Ltd
Major Depressive Disorder
1 trial -
PRAX-222
Chongqing Precision Biotech Co., Ltd
Voltage-gated sodium channel type II alpha subunit (SCN2A) developmental and epileptic encephalopathy (DEE)
1 trial -
PREDNISOLONE , PREDNISONE , -, Ifinatamab Deruxtecan, PARACETAMOL , -, DOCETAXEL , -, -, -
Merck Sharp and Dohme
Metastatic Castration-Resistant Prostate Cancer
1 trial -
PREDNISOLONE, CORTISONE ACETATE, FLUDROCORTISONE, Gohibic, TRIAMCINOLONE, PREDNISONE, DEXAMETHASONE, HYDROCORTISONE, METHYLPREDNISOLONE, IFX-1 placebo is formulated as PBS (150 mM sodium chloride, 10 mM sodium phosphate, pH 7.0) with 0.05% polysorbate 80. IFX-1 placebo is diluted in sterile 0.9% sodium chloride to the required concentration and volume. This diluent is a commercial product not accompanying IFX-1 placebo., BETAMETHASONE
InflaRx GmbH
ulcerative pyoderma gangrenosum
1 trial -
PREDNISOLONE, Placebo for Depemokimab Injection, Placebo for Prednisolone
GlaxoSmithKline
Hypereosinophilic Syndrome (HES)
1 trial -
PREDNISOLONE, Placebo pMDI to match Budesonide/Formoterol Fumarate pMDI, Placebo MDI match Budesonide, Glycopyronium and Formoterol Fumarate/ Budesonide and Formoterol Fumarate MDI, Symbicort, 160 mikrogram/4,5 mikrogram/puff inhalationsspray, suspension, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, Budesonide, Glycopyronium and Formoterol Fumarate, SALBUTAMOL
AstraZeneca AB
Severe and inadequately controlled asthma
1 trial -
PREDNISONE, BMS-986365, ENZALUTAMIDE, ABIRATERONE, DOCETAXEL, PREDNISOLONE, ABIRATERONE, ENZALUTAMIDE
Celgene Europe Limited
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1 trial -
PREDNISONE, DOXORUBICIN , BENDAMUSTINE , VINCRISTINE , VINCRISTINE, CYCLOPHOSPHAMIDE , OBINUTUZUMAB, RITUXIMAB, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, BENDAMUSTINE, RITUXIMAB, PREDNISONE , RITUXIMAB, OBINUTUZUMAB
Fondazione Telethon ETS
Follicular Lymphoma
1 trial -
PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion
Takeda
Active Ulcerative Colitis (UC) or Crohn's disease (CD)
1 trial -
PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion
Takeda
Moderately to severely active Ulcerative Colitis (UC)
1 trial -
PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion, BUDESONIDE
Takeda
Moderately to severely active Crohn's disease (CD)
1 trial -
PREDNISONE, PREDNISONE, SODIUM CHLORIDE, RITUXIMAB
Fondazione Telethon ETS
Generalized Myasthenia Gravis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources